Quarterly ibandronate benefits bone

Article

Bone mineral density (BMD) improves through up to 2 years of treatment with IV ibandronate, according to a post hoc analysis presented at the 17th annual meeting of the North American Menopause Society in Nashville, Tenn.

Bone mineral density (BMD) improves through up to 2 years of treatment with IV ibandronate, according to a post hoc analysis presented at the 17th annual meeting of the North American Menopause Society in Nashville, Tenn.

The data were reported by investigators from the DIVA (Dosing IntraVenous Administration) study, phase III comparison of daily oral (2.5 mg) or quarterly IV (3 mg) ibandronate. Nearly 1,400 women aged 55 to 80 who were postmenopausal for at least 5 years were enrolled in the double-blind, double-dummy trial. The post hoc analysis looked only at BMD in women on IV treatment for 1 to 2 years.

BMD at various sites increased from year 1 to year 2, with measurements at the lumbar spine (LS) up nearly 5% and 5.75%, respectively, up 2.21% and 2.44%, respectively, at the femoral neck, up 2.22% and 2.76%, respectively, for total hip, and up 3.6% and 4.48%, respectively, for the trochanter.

Related Videos
Fezolinetant effective against vasomotor symptoms | Image Credit: med.unc.edu
Discussing PCOS: misconceptions, management, encouragement | Image Credit: ahn.org
The importance of diversity in obstetrics | Image Credit: © stanfordchildrens.org
Study confirms efficacy of JADA against postpartum bleeding | Image Credit: © Amy Taneja MD - © Amy Taneja MD - linkedin.com.
Matthew Zerden, MD
John Stanley, MD
Marci Bowers, MD | Image Credit: Marcibowers.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.